Active	Status	Sponsor type	Region	Phase	Filter
10 Active 1 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Leath, Charles A
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer	Completed	2	79	Europe, Canada, US, RoW	Mirvetuximab soravtansine, MIRV, IMGN853	AbbVie	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	01/24	12/24
NCT06084416: A Study of Sovilnesib in Subjects with Ovarian Cancer	Recruiting	1	120	US	Sovilnesib	Volastra Therapeutics, Inc.	High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability	03/25	07/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022 Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022 Approved for recurrent or advanced endometrial cancer Dec 2021 - Dec 2021: Approved for recurrent or advanced endometrial cancer Approved for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors Aug 2021 - Aug 2021: Approved for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors Approved for recurrent or advanced 2L dMMR/MSI-H endometrial cancer Apr 2021 - Apr 2021: Approved for recurrent or advanced 2L dMMR/MSI-H endometrial cancer Approved for mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer Apr 2021 - Apr 2021: Approved for mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer Positive CHMP opinion for use as monotherapy in women with dMMR/MSI-H 2L endometrial cancer Feb 2021 - Feb 2021: Positive CHMP opinion for use as monotherapy in women with dMMR/MSI-H 2L endometrial cancer Data from the GARNET study in solid tumor at ASCO GI 2020 Jan 2021 - Jan 2021: Data from the GARNET study in solid tumor at ASCO GI 2020 Data from the GARNET study in recurrent or advanced endometrial cancer at ESMO 2020 Sep 2020 - Sep 2020: Data from the GARNET study in recurrent or advanced endometrial cancer at ESMO 2020 Data from the GARNET study in recurrent or advanced endometrial cancer Apr 2020 - Apr 2020: Data from the GARNET study in recurrent or advanced endometrial cancer Additional data from GARNET trial for advanced solid tumors Nov 2019 - Nov 2019: Additional data from GARNET trial for advanced solid tumors From GARNET trial for 2L recurrent/advanced endometrial cancer Mar 2019 - Mar 2019: From GARNET trial for 2L recurrent/advanced endometrial cancer From GARNET trial at SITC 2018 [screenshot] Nov 2018 - Nov 2018: From GARNET trial at SITC 2018 [screenshot] Additional data from GARNET trial in advanced solid tumors at SITC 2018 Nov 2018 - Nov 2018: Additional data from GARNET trial in advanced solid tumors at SITC 2018 From GARNET trial at ESMO 2018 [screenshot] Oct 2018 - Oct 2018: From GARNET trial at ESMO 2018 [screenshot] Updated data for rec or adv MSI-H endometrial cancer [GARNET] Oct 2018 - Oct 2018: Updated data for rec or adv MSI-H endometrial cancer [GARNET] From GARNET trial at AACR 2018 [screenshot] Apr 2018 - Apr 2018: From GARNET trial at AACR 2018 [screenshot] Summarized initial results Apr 2018 - Apr 2018: Summarized initial results Summarized initial results Apr 2018 - Apr 2018: Summarized initial results In solid tumors at ASCO 2017 Jun 2017 - Jun 2017: In solid tumors at ASCO 2017 More	Recruiting	1	740	Europe, Canada, US, RoW	Dostarlimab	Tesaro, Inc.	Neoplasms	05/26	10/27
Robinson, Sara
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer	Completed	2	79	Europe, Canada, US, RoW	Mirvetuximab soravtansine, MIRV, IMGN853	AbbVie	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	01/24	12/24
NCT04982835: M6®-C Artificial Cervical Disc Two-Level IDE Pivotal Study	Recruiting	N/A	263	US	M6-C Artificial Cervical Disc, ACDF	Spinal Kinetics	Cervical Disc Degenerative Disorder	12/24	12/25